Zummo Jacqueline 4
4 · Protara Therapeutics, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Protara (TARA) Chief R&D Officer Jacqueline Zummo Sells 22,598 Shares
What Happened Jacqueline Zummo, Protara Therapeutics' Chief Research & Development Officer, sold 22,598 shares on April 1, 2026, generating gross proceeds of approximately $118,865. The reported weighted-average price was $5.26 per share. This was a sale (not a purchase) and therefore generally considered routine insider selling rather than a direct bullish signal.
Key Details
- Transaction date: 2026-04-01; Form 4 filed: 2026-04-02 (appears timely).
- Shares sold: 22,598; weighted-average price: $5.26; total proceeds: ~$118,865.
- Price range: individual sales occurred between $5.25 and $5.31 (F2).
- Shares owned after transaction: not specified in the provided filing.
- Footnote F1: Sale occurred automatically under a Rule 10b5-1 trading plan established 12/31/2025.
- Footnote F2: Weighted-average price shown; reporting person can provide per-price breakdown on request.
Context The sale was executed under a pre-established 10b5-1 plan, indicating it was an automated, pre-planned disposition rather than an ad-hoc trade based on new information. For retail investors, purchases generally carry more informational weight than routine sales; a 10b5-1 sale is commonly used for liquidity or diversification and should not be interpreted on its own as a change in insider confidence.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-04-01$5.26/sh−22,598$118,865→ 95,961 total
Footnotes (2)
- [F1]The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.